LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a new international study, published in the November 2015 issue of Clinical Ophthalmology, showed that two iStent® Trabecular Micro-Bypass Stents provided “statistically significant, sustained and safe reduction in intraocular
BOSTON–(BUSINESS WIRE)–Vision Medicines announces exclusive worldwide license from Case Western Reserve University for drug candidate for Stargardt disease. Stargardt leads to legal blindness.
BOSTON–(BUSINESS WIRE)–Vision Medicines announces largest co-funding agreement to date with Foundation Fighting Blindness for Stargardt disease program. Stargardt is an orphan disease that leads to legal blindness.
OSAKA, Japón–(BUSINESS WIRE)–Santen Pharmaceutical Co., Ltd. (en lo sucesivo, Santen) ha anunciado hoy que el National Institute for Health and Care Excellence (NICE) ha publicado un dictamen positivo (Final Appraisal Determination, FAD) por el que recomienda el uso del fármaco de Santen IKERVIS® (ciclosporina colirio en solución 1 mg/ml en envases unidosis) en Inglaterra para el tratamiento de la queratitis aguda en pacientes adultos con sequedad ocular que no han experimentado una mejoría d
NEW YORK — At OSN New York 2015, Alan R. Faulkner, MD, discusses femtosecond cataract surgery in eyes with corneal conditions such as keratoconus, corneal scars, previous intacs and Fuch’s dystrophy.
(MedPage Today) — Also, White House releases official text of controversial Pacific trade deal